Treatment of Indolent Systemic Mastocytosis With PA101

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in adult patients with indolent systemic mastocytosis (ISM). The purpose of the study is to determine the efficacy and safety profile of PA101 delivered via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using standard treatments.
Epistemonikos ID: 99136337da67e1c0c7b19179ce0c6a16f4f8657b
First added on: May 12, 2024